Soybean-derived Bowman-Birk inhibitor (BBI) blocks HIV entry into macrophages

Virology. 2018 Jan 1:513:91-97. doi: 10.1016/j.virol.2017.08.030. Epub 2017 Oct 16.

Abstract

Bowman-Birk inhibitor (BBI) is a soybean-derived protease inhibitor that has anti-inflammation and anti-HIV effect. Here, we further investigated the anti-HIV action of BBI in macrophages, focusing on its effect on viral entry. We found that BBI could significantly block HIV entry into macrophages. Investigation of the mechanism(s) of the BBI action on HIV inhibition showed that BBI down-regulated the expression of CD4 receptor (as much as 80%) and induced the production of the CC chemokines (up to 60 folds at protein level) in macrophages. This inhibitory effect of BBI on HIV entry could be blocked by the neutralization antibodies to CC chemokines. These findings indicate that BBI may have therapeutic potential as a viral entry inhibitor for the prevention and treatment of HIV infection.

Keywords: Bowman-Birk inhibitor; CC chemokine; CCR5; CD4; HIV.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD4 Antigens / biosynthesis
  • Cells, Cultured
  • Chemokines / biosynthesis
  • Gene Expression Regulation / drug effects
  • HIV / drug effects*
  • HIV / physiology*
  • HIV Fusion Inhibitors / metabolism*
  • Humans
  • Macrophages / virology*
  • Trypsin Inhibitor, Bowman-Birk Soybean / metabolism*
  • Virus Internalization / drug effects*

Substances

  • CD4 Antigens
  • Chemokines
  • HIV Fusion Inhibitors
  • Trypsin Inhibitor, Bowman-Birk Soybean